Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.56

€0.56

-0.710%
-0.004
-0.710%
-
 
12.12.25 / Stuttgart Stock Exchange WKN: A0B6SJ / Name: PST / Stock / Construction & Engineering / Micro Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for PST

sharewise wants to provide you with the best news and tools for PST, so we directly link to the best financial data sources.

News

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck CancerPhoto, wide shot, wide-angle lens,  Janitorial service, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/4d4e885c-79e9-4b8f-bd91-e9721cd7c2e9.png
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Key Points

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal DataPhoto, wide shot, wide-angle lens,  Janitorial service, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/4d4e885c-79e9-4b8f-bd91-e9721cd7c2e9.png
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its

Bicara Therapeutics Q1 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Janitorial service, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/4d4e885c-79e9-4b8f-bd91-e9721cd7c2e9.png
Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA